What is molgramostim?

Molgramostim nebulizer solution (molgramostim) is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara is developing an inhaled formulation as a potential treatment option for aPAP. We believe that inhalation of molgramostim activates macrophages in the lung alveoli, thus potentially restoring the surfactant-clearing activity of the alveolar macrophages and considerably improving oxygenation.

Molgramostim has been granted Orphan Drug Designation for the treatment of aPAP by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency (EMA), Fast Track Designation and Breakthrough Therapy Designation by the FDA, and Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Learn about our clinical trials in molgramostim.

Explore the data